329 related articles for article (PubMed ID: 22521546)
1. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.
Goyal J; Antonarakis ES
Cancer Lett; 2012 Oct; 323(2):135-46. PubMed ID: 22521546
[TBL] [Abstract][Full Text] [Related]
2. Bone-targeting radiopharmaceuticals including radium-223.
Brady D; Parker CC; O'Sullivan JM
Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
5. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Cheetham PJ; Petrylak DP
Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
[TBL] [Abstract][Full Text] [Related]
6. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
7. Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions.
Dash A; Das T; Knapp FFR
Curr Med Chem; 2020; 27(19):3187-3249. PubMed ID: 30714520
[TBL] [Abstract][Full Text] [Related]
8. [Targeted radionuclide therapy for castration-resistant prostate cancer].
Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
10. Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Bouman-Wammes EW; de Klerk JMH; Bloemendal HJ; Van Dodewaard-de Jong JM; Lange R; Ter Heine R; Verheul HMW; Van den Eertwegh AJM
Clin Genitourin Cancer; 2019 Apr; 17(2):e281-e292. PubMed ID: 30555024
[TBL] [Abstract][Full Text] [Related]
11. Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium.
Rubini G; Nicoletti A; Rubini D; Asabella AN
Cancer Biother Radiopharm; 2014 Feb; 29(1):1-11. PubMed ID: 24180669
[TBL] [Abstract][Full Text] [Related]
12. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
13. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
Bauman G; Charette M; Reid R; Sathya J
Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
Dorff TB; Agarwal N
Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
[TBL] [Abstract][Full Text] [Related]
15. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
16. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.
Patel CM; Wadas TJ; Shiozawa Y
Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705
[TBL] [Abstract][Full Text] [Related]
17. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
19. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Fizazi K; Beuzeboc P; Lumbroso J; Haddad V; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Theodore C; Loriot Y; Tournay E; Bouzy J; Laplanche A
J Clin Oncol; 2009 May; 27(15):2429-35. PubMed ID: 19364971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]